trial
as of 2026-07-01Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
NCTId NCT05859698
at a glance
Phase 4 · Completed
Enrollment 59 (actual)
Sponsored by Neurocrine Biosciences
Primary completion 2024-12-27
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
59 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2023-05-09
Primary completion
2024-12-27
Eligibility
ALL · 18 Years
Interventions & indications
Sponsors
Neurocrine BiosciencesLead Sponsor
Investigators
1
Clinical Development LeadStudy Director
Sites
18 total
Bryant, United StatesAnaheim, United StatesOrange, United StatesTorrance, United StatesBonita Springs, United StatesMiami, United StatesMiami Lakes, United StatesOkeechobee, United StatesTampa, United StatesAtlanta, United StatesAugusta, United StatesMarietta, United States
Facts & assertions
4 sourced
Enrollment
59
Phase
PHASE4
Primary Completion Date
2024-12-27
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
investigator